Paxlovid Weaker Against Current COVID-19 Variants

A real-world study found that Pfizer's COVID-19 antiviral Paxlovid is now less effective at preventing hospitalization or death in high-risk patients as compared with earlier studies.

Related Keywords

Cleveland Clinic ,Florida ,United States , ,Bloomberg ,Medscape Coronavirus Resource Center ,Coronavirus Resource ,North Carolina Gillings School ,Global Public Health ,Molnupiravir Use ,Severe Outcomes From Omicron Infections ,First Oral Antiviral ,Study Shows ,